-
公开(公告)号：US20080027066A1
公开(公告)日：2008-01-31
申请号：US11782415
申请日：2007-07-24
申请人： Dale Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shacham , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
发明人： Dale Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shacham , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
IPC分类号： A61K31/495 , A61P25/00 , C07D241/04
CPC分类号： C07D213/74 , C07D211/96 , C07D239/42 , C07D295/13 , C07D401/12
摘要： The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
摘要翻译： 本发明涉及5-HT受体激动剂或拮抗剂。 公开了由式I表示的新型芳基哌嗪基磺酰胺化合物及其用于治疗包括由5-HT受体直接或间接介导的疾病的疾病的合成和用途。 这些病症包括中枢神经系统疾病，如广泛性焦虑症，ADD / ADHD，神经损伤，中风和偏头痛。 还包括制备方法和新型中间体及其药物盐。
-
公开(公告)号：US20070004742A1
公开(公告)日：2007-01-04
申请号：US11516345
申请日：2006-09-05
申请人： Dale Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shachem , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
发明人： Dale Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shachem , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
IPC分类号： A61K31/497 , A61K31/496 , A61K31/506 , C07D403/02 , A61K31/4965 , C07D241/02
CPC分类号： C07D213/74 , C07D211/96 , C07D239/42 , C07D295/13 , C07D401/12
摘要： The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
摘要翻译： 本发明涉及5-HT受体激动剂或拮抗剂。 公开了由式I表示的新型芳基哌嗪基磺酰胺化合物及其用于治疗包括由5-HT受体直接或间接介导的疾病的疾病的合成和用途。 这些病症包括中枢神经系统疾病，如广泛性焦虑症，ADD / ADHD，神经损伤，中风和偏头痛。 还包括制备方法和新型中间体及其药物盐。
-
公开(公告)号：US07488731B2
公开(公告)日：2009-02-10
申请号：US11782415
申请日：2007-07-24
申请人： Dale S. Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa R. Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shacham , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
发明人： Dale S. Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa R. Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shacham , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
IPC分类号： A61K31/495 , C07D295/13
CPC分类号： C07D213/74 , C07D211/96 , C07D239/42 , C07D295/13 , C07D401/12
摘要： The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
-
公开(公告)号：US07491727B2
公开(公告)日：2009-02-17
申请号：US11516345
申请日：2006-09-05
申请人： Dale S. Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa R. Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shacham , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
发明人： Dale S. Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa R. Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shacham , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
IPC分类号： A61K31/495 , A61K31/496
CPC分类号： C07D213/74 , C07D211/96 , C07D239/42 , C07D295/13 , C07D401/12
摘要： The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
摘要翻译： 本发明涉及5-HT受体激动剂或拮抗剂。 公开了由式I表示的新型芳基哌嗪基磺酰胺化合物及其用于治疗包括由5-HT受体直接或间接介导的疾病的疾病的合成和用途。 这些病症包括中枢神经系统疾病，如广泛性焦虑症，ADD / ADHD，神经损伤，中风和偏头痛。 还包括制备方法和新型中间体及其药物盐。
-
公开(公告)号：US07153858B2
公开(公告)日：2006-12-26
申请号：US10768579
申请日：2004-01-30
申请人： Dale S. Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa Rao Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shachem , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
发明人： Dale S. Dhanoa , Dongli Chen , Oren Becker , Silvia Noiman , Srinivasa Rao Cheruku , Yael Marantz , Anurag Sharadendu , Sharon Shachem , Alexander Heifetz , Pradyumna Mohanty , Boaz Inbal , Merav Fichman , Raphael Nudelman , Shay Bar-Haim
IPC分类号： A61K31/495 , A61K31/496 , C07D295/13 , C07D401/06 , A61K31/506 , C07D403/04
CPC分类号： C07D213/74 , C07D211/96 , C07D239/42 , C07D295/13 , C07D401/12
摘要： The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formulae I: and II, and synthesis and uses of those compounds for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
摘要翻译： 本发明涉及5-HT受体激动剂或拮抗剂。 公开了由式I和II表示的新型芳基哌嗪基磺酰胺化合物，以及用于治疗包括由5-HT受体直接或间接介导的那些疾病的那些化合物的合成和用途。 这些病症包括中枢神经系统疾病，如广泛性焦虑症，ADD / ADHD，神经损伤，中风和偏头痛。 还包括制备方法和新型中间体及其药物盐。
-
公开(公告)号：US20120245116A1
公开(公告)日：2012-09-27
申请号：US13491752
申请日：2012-06-08
IPC分类号： A61K31/7056 , A61K31/197 , A61K31/343
CPC分类号： A61K38/063 , A61K31/365 , A61K31/7056 , Y10S514/824
摘要： Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
摘要翻译： 需要NO供体治疗或抑制病理增殖细胞或增加NO生物活性的患者用治疗有效量的谷胱甘肽依赖性甲醛脱氢酶抑制剂治疗。
-
公开(公告)号：US20070111949A1
公开(公告)日：2007-05-17
申请号：US11648406
申请日：2006-12-29
IPC分类号： A61K38/05 , A61K31/365
CPC分类号： A61K38/063 , A61K31/365 , A61K31/7056 , Y10S514/824
摘要： Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
摘要翻译： 需要NO供体治疗或抑制病理增殖细胞或增加NO生物活性的患者用治疗有效量的谷胱甘肽依赖性甲醛脱氢酶抑制剂治疗。
-
公开(公告)号：US20100015121A1
公开(公告)日：2010-01-21
申请号：US12566006
申请日：2009-09-24
IPC分类号： A61K38/44 , A61K38/06 , A61P11/00 , A61P15/10 , A61K31/34 , A61P9/10 , A61P7/00 , A61P1/16 , A61P9/00
CPC分类号： A61K38/063 , A61K31/365 , A61K31/7056 , Y10S514/824
摘要： Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
摘要翻译： 需要NO供体治疗或抑制病理增殖细胞或增加NO生物活性的患者用治疗有效量的谷胱甘肽依赖性甲醛脱氢酶抑制剂治疗。
-
公开(公告)号：US07615535B2
公开(公告)日：2009-11-10
申请号：US11648406
申请日：2006-12-29
IPC分类号： A61K38/05
CPC分类号： A61K38/063 , A61K31/365 , A61K31/7056 , Y10S514/824
摘要： Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
摘要翻译： 需要NO供体治疗或抑制病理增殖细胞或增加NO生物活性的患者用治疗有效量的谷胱甘肽依赖性甲醛脱氢酶抑制剂治疗。
-
公开(公告)号：US07179791B2
公开(公告)日：2007-02-20
申请号：US09757610
申请日：2001-01-11
IPC分类号： A61K38/00 , A61K31/34 , A61K31/195
CPC分类号： A61K38/063 , A61K31/365 , A61K31/7056 , Y10S514/824
摘要： Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
摘要翻译： 需要NO供体治疗或抑制病理增殖细胞或增加NO生物活性的患者用治疗有效量的谷胱甘肽依赖性甲醛脱氢酶抑制剂治疗。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.05 秒)
